Munich Cancer Registry



- Survival
- Selection Matrix
- ► Homepage
- ▶ Deutsch

ICD-10 C74: Adrenal cancer

Incidence and Mortality

Year of diagnosis	1998-2020
Patients	293
Diseases	294
Creation date	12/21/2021
Database export	12/20/2021
Population	4.95 m



Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/base/bC74_E-ICD-10-C74-Adrenal-cancer-incidence-and-mortality.pdf

Index of figures and tables

Fig./10	l.	Page
1	Annual cases, DCO, mult. malignancies, follow-up / yr	4
2	Incidence by year of diagnosis	7
3	Age distribution parameters by year of diagnosis	8
4	Age distribution by 5-year age group and sex	11
5	Age-specific incidence, DCO rate, proportion malignancies	12
6	Age distribution and age-specific incidence (chart)	13
6a	Age-specific incidence internationally (chart)	14
7	Standardized incidence ratio of further malignancies	15
8a	Map of cancer incidence (BRD-S) by county (chart)	17
8b	Standardized incidence ratio (SIR) by county (chart)	18
9a	Pts incident cohorts and mortality / yr	19
9b	Incidence and mortality by year of diagnosis	20
9c	Cancer-related deaths, death certification available / yr	21
10	Medians of age at death / yr	22
11	Mortality by year of death	24
12	Distribution of age at death	26
13	Age-specific mortality	27
14	Further malignancies in deaths	28
15	Age-specific mortality (first primaries)	29
16	Age-specific mortality (single primaries)	30
17	Age distribution and age-specific mortality (chart)	31
18a	Map of cancer mortality (BRD-S) by county (chart)	32
18b	Standardized mortality ratio (SMR) by county (chart)	33



Global Statements about the statistics on the Internet -

Baseline Statistics (grey button ____), Survival (red button ____)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.69 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases^{###} are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, December 2021

- [#] Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.65 million to 4.10 in 2002, and to 4.69 million in 2007).
- ^{##} Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- ### DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate.

ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
C74 C74.0 C74.1 C74.9	Malignant neoplasm of adrenal gland Cortex of adrenal gland Medulla of adrenal gland Adrenal gland, unspecified

INCIDENCE

Table 1

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (ALL PATIENTS) (incl. DCO)

				Prop.			
				at least	Prop.		
				1 further	at least		
				malign.	1 further		Prop.
	All	DCO	Prop.	prior +	malign.	Prop.	actively
Year of	cases	cases	DCO	synchron.	after	deaths	followed
diagnosis	n	n	00	9	26	00	90
2							
1998	8			37.5	5.6	37.5	100.0
1999	7	1	14.3	26.7	5.7	85.7	100.0
2000	9	1	11.1	20.8	4.7	77.8	100.0
2001	9	1	11.1	15.2	4.5	55.6	88.9
2002	7			12.5	4.3	85.7	100.0 #
2003	11 /	/1	9.1	11.8	4.0	72.7	100.0
2004	16	1	6.3	10.4	4.2	56.3	100.0
2005	12	2	16.7	8.9	3.6	50.0	83.3
2006	13			9.8	3.3	76.9	100.0
2007	12			9.6	3.0	58.3	100.0 #
2008	10			8.8	3.2	70.0	100.0
2009	15	1	6.7	9.3	2.8	46.7	100.0
2010	16			10.3	3.1	75.0	93.8
2011	17			11.1	2.8	52.9	100.0
2012	18	3	16.7	12.2	3.1	61.1	88.9
2013	22	2	9.1	12.9	3.6	40.9	100.0
2014	20	2	10.0	13.1	1.1	65.0	95.0
2015	14			12.3	1.4	71.4	100.0
2016	16	2	12.5	12.7	0.0	56.3	100.0
2017	15	2	13.3	12.7	0.0	46.7	100.0
2018	12			14.3	0.0	50.0	100.0
2019	8			14.3	0.0	50.0	100.0
2020	7			15.3	0.0	14.3	100.0 ##
1998-2020	294	19	6.5	15.3	5.6	58.5	97.6

294 cases diagnosed 1998-2020 are related to a total of 293 patients. Currently, in 61 (20.8 %) of these 293 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 48 / 6 / 7 (16.4 % / 2.0 % / 2.4 %) patients exist having 2 / 3 / 4+ malignancies.

- # The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.
- ## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retreived from the respective headings.

How to interpret:

In 2018, a subgroup of 12 cases has been diagnosed, of which 14.3 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1a

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (MALES) (incl. DCO)

			DCO	Prop.	Prop. at least 1 further malign. prior +	Prop. at least 1 further malign.	Prop.	Prop. actively
Year of	Males	Males	cases	DCO	synchron.	after	deaths	followed
diagnosis	n	00	n	00	00	olo	00	00
1998	1	12.5			0.0	6.2		100.0
1999	2	28.6			33.3	6.2	50.0	100.0
2000	6	66.7	1	16.7	11.1	4.7	83.3	100.0
2001	3	33.3			8.3	4.1	33.3	100.0
2002	3	42.9			6.7	4.2	66.7	100.0 #
2003	3	27.3			5.6	4.3	66.7	100.0
2004	7	43.8	1	14.3	4.0	4.5	85.7	100.0
2005	8	66.7	1	12.5	3.0	2.9	37.5	87.5
2006	6	46.2			5.1	2.1	66.7	100.0
2007	6	50.0			4.4	1.1	66.7	100.0 #
2008	3	30.0			4.2	1.2	66.7	100.0
2009	6	40.0	1	16.7	5.6	1.2	33.3	100.0
2010	7	43.8			6.6	1.3	57.1	100.0
2011	9	52.9			7.1	1.4	55.6	100.0
2012	11	61.1			11.1	1.7	45.5	81.8
2013	12	54.5			11.8	2.0	25.0	100.0
2014	10	50.0	1	10.0	12.6	0.0	60.0	90.0
2015	5	35.7			12.0	0.0	60.0	100.0
2016	9	56.3	1	11.1	13.7	0.0	44.4	100.0
2017	6	40.0			13.8	0.0	66.7	100.0
2018	5	41.7			16.4	0.0	80.0	100.0
2019	3	37.5			16.0	0.0	33.3	100.0
2020	3	42.9			16.4	0.0	33.3	100.0 ##
1998-2020	134	45.6	6	4.5	16.4	6.2	53.7	97.0

134 cases diagnosed 1998-2020 are related to a total of 133 patients. Currently, in 29 (21.8 %) of these 133 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 21 / 2 / 6 (15.8 % / 1.5 % / 4.5 %) patients exist having 2 / 3 / 4+ malignancies.

- # The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.
- ## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retreived from the respective headings.

How to interpret:

In 2018, a subgroup of 5 cases has been diagnosed, of which 16.4 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1b

Cases with invasive cancer by year of diagnosis, proportions of DCO, further malignancies, deaths, and active follow-up (FEMALES) (incl. DCO)

					Prop.			
					at least	Prop.		
					1 further			
					malign.	1 further		Prop.
			DCO	Prop.	prior +	malign.	Prop.	actively
Year of	Females	Females	cases	DCO	synchron.	after	deaths	followed
diagnosis	n	00	n	00	90	olo	00	olo
1998	7	87.5			42.9	5.1	42.9	100.0
1999	5	71.4	1	20.0	25.0	5.3	100.0	100.0
2000	3	33.3			26.7	4.8	66.7	100.0
2001	6	66.7	1	16.7	19.0	4.9	66.7	83.3
2002	4	57.1			16.0	4.3	100.0	100.0 #
2003	8	72.7	1	12.5	15.2	3.7	75.0	100.0
2004	9	56.3			14.3	4.0	33.3	100.0
2005	4	33.3	1	25.0	13.0	4.3	75.0	75.0
2006	7	53.8			13.2	4.4	85.7	100.0
2007	6	50.0			13.6	4.7	50.0	100.0 #
2008	7	70.0			12.1	5.0	71.4	100.0
2009	9	60.0			12.0	4.3	55.6	100.0
2010	9	56.3			13.1	4.7	88.9	88.9
2011	8	47.1			14.1	3.9	50.0	100.0
2012	7	38.9	3	42.9	13.1	4.4	85.7	100.0
2013	10	45.5	2	20.0	13.8	4.9	60.0	100.0
2014	10	50.0	1	10.0	13.4	2.0	70.0	100.0
2015	9	64.3			12.5	2.4	77.8	100.0
2016	7	43.8	1	14.3	11.9	0.0	71.4	100.0
2017	9	60.0	2	22.2	11.8	0.0	33.3	100.0
2018	7	58.3			12.6	0.0	28.6	100.0
2019	5	62.5			12.8	0.0	60.0	100.0
2020	4	57.1			14.4	0.0		100.0 ##
1998-2020	160	54.4	13	8.1	14.4	5.1	62.5	98.1

160 cases diagnosed 1998-2020 are related to a total of 160 patients. Currently, in 32 (20.0 %) of these 160 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 27 / 4 / 1 (16.9 % / 2.5 % / 0.6 %) patients exist having 2 / 3 / 4+ malignancies.

- # The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.
- ## Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retreived from the respective headings.

How to interpret:

In 2018, a subgroup of 7 cases has been diagnosed, of which 12.6 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Incidence measures by year of diagnosis including DCO cases (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

			Malaa	T. a.m.	Malaa		Malaa		Malaa	
Veen of	Malaa	Temelee	Males		Males		Males		Males	
Year of		Females		Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.
diagnosis	n	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
		_								
1998	1	7	0.1	0.6	0.2	0.7	0.1	0.6	0.1	0.6
1999	2	5	0.2	0.4	0.3	0.2	0.2	0.3	0.2	0.4
2000	6	3	0.5	0.2	0.4	0.3	0.5	0.3	0.5	0.3
2001	3	6	0.3	0.5	0.5	0.5	0.4	0.5	0.2	0.5
2002	3	4	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.2
2003	3	8	0.2	0.4	0.3	0.4	0.2	0.4	0.1	0.4
2004	7	9	0.4	0.5	0.2	0.7	0.3	0.6	0.4	0.4
2005	8	4	0.4	0.2	0.5	0.2	0.5	0.2	0.5	0.2
2006	6	7	0.3	0.3	0.2	0.2	0.3	0.3	0.3	0.3
2007	6	6	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.2
2008	3	7	0.1	0.3	0.1	0.2	0.1	0.2	0.1	0.3
2009	6	9	0.3	0.4	0.3	0.3	0.3	0.4	0.2	0.4
2010	7	9	0.3	0.4	0.5	0.3	0.4	0.3	0.3	0.4
2011	9	8	0.4	0.3	0.5	0.4	0.5	0.4	0.4	0.3
2012	11	7	0.5	0.3	0.5	0.2	0.5	0.2	0.5	0.2
2013	12	10	0.5	0.4	0.7	0.3	0.6	0.3	0.5	0.3
2014	10	10	0.4	0.4	0.2	0.2	0.3	0.3	0.4	0.4
2015	5	9	0.2	0.4	0.2	0.4	0.2	0.4	0.2	0.4
2016	9	7	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.3
2017	6	9	0.2	0.4	0.2	0.3	0.2	0.3	0.2	0.3
2018	5	7	0.2	0.3	0.1	0.3	0.1	0.3	0.2	0.3
2019	3	5	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.2
2020	3	4	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1
1998-2020	134	160	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3

The computation of the incidence measures includes all cancers, irrespective of first or subsequent malignancy.

Age distribution parameters by year of diagnosis (ALL PATIENTS) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
-										
1998	8	37.1	30,9	0.1	66.7	0.1	0.6	53.1	61.4	66.7
1999	7	56.8	28.1	4.8	83.1	4.8	31.1	70.1	72.6	83.1
2000	9	54.2	25.1	4.6	75.5	4.6	61.1	63.0	66.0	75.5
2001	9	34.0	27.9	0.1	77.8	0.1	4.1	33.2	53.8	77.8
2002	7	35.6	32.9	0.1	76.1	0.1	1.1	47.9	67.2	76.1
2003	11	41.4	30.9	0.3	78.5	0.8	2.5	56.6	64.2	71.3
2004	16	45.6	32.5	2.0	84.6	2.1	7.0	52.7	73.7	83.8
2005	12	45.9	35.0	0.3	87.9	0.6	2.8	51.6	76.4	79.4
2006	13	57.4	14.0	40.3	81.5	42.2	43.9	54.8	64.9	77.6
2007	12	36.1	29.6	0.0	80.5	0.0	4.4	38.0	62.2	72.7
2008	10	60.5	27.0	1.4	88.2	15.0	56.1	66.3	80.9	85.9
2009	15	48.0	22.5	2.0	78.7	5.5	39.6	52.6	62.7	77.6
2010	16	39.6	31.6	0.0	82.7	0.1	3.9	38.7	69.7	77.4
2011	17	38.8	28.3	0.0	78.5	0.1	1.5	47.7	56.4	74.1
2012	18	56.0	26.5	0.1	90.4	0.3	49.7	61.9	69.5	88.9
2013	22	50.7	33.7	0.0	94.5	0.4	25.6	56.1	80.2	91.9
2014	20	63.8	16.4	26.9	86.4	43.6	49.1	64.6	76.4	83.6
2015	14	47.1	23.8	1.7	80.3	2.2	36.7	49.3	61.5	74.0
2016	16	51.2	25.2	0.0	83.1	4.3	36.4	55.6	71.8	75.4
2017	15	53.2	24.9	3.2	96.7	23.8	30.0	57.0	74.0	76.0
2018	12	56.0	25.0	23.0	85.9	24.7	30.8	60.7	78.6	83.6
2019	8	53.2	8.7	39.9	60.5	39.9	44.5	58.6	59.4	60.5
2020	7	66.4	6.7	59.3	77.7	59.3	60.2	66.1	71.8	77.7
1998-2020	294	49.3	27.3	0.0	96.7	1.5	29.7	56.6	71.2	79.4

Table 3a

Age distribution parameters by year of diagnosis (MALES) (incl. DCO)

Cases		Std.					Median		
n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1	0.8		0.8	0.8	0.8	0.8	0.8	0.8	0.8
2	37.7	46.5	4.8	70.6	4.8	4.8	37.7	70.6	70.6
6	55.9	25.6	4.6	75.5	4.6	62.4	63.4	66.0	75.5
3	17.3	29.3	0.1	51.2	0.1	0.1	0.8	51.2	51.2
3	17.8	26.1	1.1	47.9	1.1	1.1	4.4	47.9	47.9
3	22.4	36.3	0.3	64.2	0.3	0.3	2.5	64.2	64.2
7	69.4	12.5	47.5	83.8	47.5	57.8	72.4	77.9	83.8
8	43.5	36.5	0.6	87.9	0.6	2.8	51.6	75.3	87.9
6	58.8	13.5	42.2	77.6	42.2	43.9	62.0	64.9	77.6
6	28.0	25.1	0.0	60.7	0.0	0.0	29.7	48.0	60.7
3	61.8	8.2	56.1	71.2	56.1	56.1	57.9	71.2	71.2
6	39.4	19.2	2.0	54.9	2.0	39.6	43.8	52.6	54.9
7	24.8	34.5	0.0	82.7	0.0	0.1	3.5	63.9	82.7
9	39.6	31.2	0.5	78.5	0.5	1.5	50.7	55.9	78.5
11	51.9	24.4	0.3	88.9	15.0	49.1	60.5	62.7	63.7
12	37.6	32.2	0.0	84.0	0.4	2.3	36.1	65.5	78.1
10	64.8	12.2	41.2	81.1	45.5	62.3	64.6	76.0	78.9
5	50.4	28.3	2.2	74.0	2.2	50.2	58.9	66.5	74.0
9	53.5	25.0	0.0	75.4	0.0	48.8	57.3	73.8	75.4
6	58.0	21.4	23.8	76.0	23.8	41.2	66.5	74.0	76.0
5	74.7	10.5	56.5	83.6	56.5	75.9	77.6	79.7	83.6
3	54.2	10.2	42.4	60.5	42.4	42.4	59.7	60.5	60.5
3	68.0	8.9	60.2	77.7	60.2	60.2	66.1	77.7	77.7
134	47.6	28.0	0.0	88.9	0.8	25.6	56.8	70.6	77.6
	n 1 2 6 3 3 7 8 6 6 3 7 8 6 6 3 6 7 9 11 12 10 5 9 6 5 3 3	n Mean 1 0.8 2 37.7 6 55.9 3 17.3 3 17.8 3 22.4 7 69.4 8 43.5 6 58.8 6 28.0 3 61.8 6 39.4 7 24.8 9 39.6 11 51.9 12 37.6 10 64.8 5 50.4 9 53.5 6 58.0 5 74.7 3 54.2 3 68.0	n Mean dev. 1 0.8 2 37.7 46.5 6 55.9 25.6 3 17.3 29.3 3 17.8 26.1 3 22.4 36.3 7 69.4 12.5 8 43.5 36.5 6 58.8 13.5 6 28.0 25.1 3 61.8 8.2 6 39.4 19.2 7 24.8 34.5 9 39.6 31.2 11 51.9 24.4 12 37.6 32.2 10 64.8 12.2 5 50.4 28.3 9 53.5 25.0 6 58.0 21.4 5 74.7 10.5 3 54.2 10.2 3 68.0 8.9 3 68.0 8.9	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$				

Table 3b

Age distribution parameters by year of diagnosis (FEMALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	7	42.3	29.3	0.1	66.7	0.1	0.3	57.1	64.8	66.7
1999	5	64.5	19.7	31.1	83.1	31.1	65.8	70.1	72.6	83.1
2000	3	50.7	29.3	17.7	73.4	17.7	17.7	61.1	73.4	73.4
2001	6	42.3	25.5	4.1	77.8	4.1	29.7	43.5	55.0	77.8
2002	4	49.0	34.0	0.1	76.1	0.1	26.3	59.8	71.7	76.1
2003	8	48.6	27.8	0.8	78.5	0.8	28.4	59.5	66.9	78.5
2004	9	27.2	31.4	2.0	84.6	2.0	5.8	7.1	43.4	84.6
2005	4	50.6	36.7	0.3	79.4	0.3	23.2	61.3	77.9	79.4
2006	7	56.1	15.4	40.3	81.5	40.3	43.7	54.7	72.2	81.5
2007	6	44.1	33.9	0.2	80.5	0.2	8.6	51.5	72.7	80.5
2008	7	59.9	32.8	1.4	88.2	1.4	28.6	75.5	83.5	88.2
2009	9	53.7	23.7	5.5	78.7	5.5	51.9	60.3	64.2	78.7
2010	9	51.1	25.4	4.3	77.4	4.3	32.7	55.7	72.7	77.4
2011	8	38.0	26.7	0.0	70.3	0.0	13.8	44.3	58.6	70.3
2012	7 /	62.5	30.2	0.1	90.4	0.1	53.0	69.5	85.8	90.4
2013	10	66.3	29.7	0.4	94.5	21.9	51.6	72.8	91.9	94.3
2014	10	62.8	20.4	26.9	86.4	36.5	46.2	65.6	83.1	85.2
2015	9	45.3	22.6	1.7	80.3	1.7	36.7	45.8	61.4	80.3
2016	7	48.3	27.2	4.3	83.1	4.3	27.6	43.1	69.8	83.1
2017	9	50.0	27.8	3.2	96.7	3.2	30.0	56.0	64.1	96.7
2018	7	42.6	23.9	23.0	85.9	23.0	24.7	35.5	64.8	85.9
2019	5	52.5	8.8	39.9	59.0	39.9	46.5	58.6	58.7	59.0
2020	4	65.2	5.8	59.3	71.8	59.3	60.5	64.9	70.0	71.8
1998-2020	160	50.8	26.6	0.0	96.7	4.2	31.9	56.5	72.0	82.3


Age distribution by 5-year age group and sex for period 2007-2020 (incl. DCO)

Age at									
diagnosis	Cases			Males			Females		
Years	n	00	Cum.%	n	00	Cum.%	n	00	Cum.%
0-4	27	13.4	13.4	17	17.9	17.9	10	9.3	9.3
5-9	2	1.0	14.4			17.9	2	1.9	11.2
10-14	0	0.0	14.4			17.9			11.2
15-19	1	0.5	14.9	1	1.1	18.9			11.2
20-24	5	2.5	17.3	3	3.2	22.1	2	1.9	13.1
25-29	13	6.4	23.8	3	3.2	25.3	10	9.3	22.4
30-34	1	0.5	24.3			25.3	1	0.9	23.4
35-39	8	4.0	28.2	3	3.2	28.4	5	4.7	28.0
40 - 44	11	5.4	33.7	4	4.2	32.6	7	6.5	34.6
45-49	14	6.9	40.6	7	7.4	40.0	7	6.5	41.1
50-54	8	4.0	44.6	5	5.3	45.3	3	2.8	43.9
55-59	23	11.4	55.9	12	12.6	57.9	11	10.3	54.2
60-64	23	11.4	67.3	12	12.6	70.5	11	10.3	64.5
65-69	12	5.9	73.3	5	5.3	75.8	7	6.5	71.0
70-74	15	7.4	80.7	8	8.4	84.2	7	6.5	77.6
75-79	16	7.9	88.6	10	10.5	94.7	6	5.6	83.2
80-84	13	6.4	95.0	4	4.2	98.9	9	8.4	91.6
85+	10	5.0	100.0	1	1.1	100.0	9	8.4	100.0
All ages	202	100.0		95	100.0		107	100.0	

Age-specific incidence, DCO rate and proportion of all cancers for period 2007-2020

							Males	Females
			Males	Females	Males	Females	Prop.all	Prop.all
Age at			Age-	Age-	DCO rate	DCO rate	cancers	cancers
diagnosis	Males	Females	spec.	spec.	n=3	n=9	n=153686	n=155051
Years	n	n	incid.	incid.	00	00	00	00
0- 4	17	10	1.0	0.6			7.7	5.8
5- 9		2		0.1				2.0
10-14								
15-19	1		0.1				0.3	
20-24	3	2	0.1	0.1			0.5	0.4
25-29	2	10	0.1	0.4			0.2	0.8
30-34		1		0.0				0.0
35-39	3	5	0.1	0.2			0.2	0.1
40 - 44	4	7	0.2	0.3			0.1	0.1
45-49	7	7	0.3	0.3			0.1	0.1
50-54	5	3	0.2	0.1	20.0	33.3	0.1	0.0
55-59	12	11	0.6	0.5		9.1	0.1	0.1
60-64	12	11	0.7	0.6			0.1	0.1
65-69	5	7	0.3	0.4	20.0	28.6	0.0	0.0
70-74	8	7	0.5	0.4			0.0	0.0
75-79	10	6	0.8	0.4	10.0		0.0	0.0
80-84	4	9	0.6	0.8			0.0	0.1
85+	1	9	0.2	0.9		55.6	0.0	0.1
All ages	94	107			3.2	8.4	0.1	0.1
Incidence								
Raw			0.3	0.3				
WS			0.3	0.3				
ES			0.3	0.3				
BRD-S			0.3	0.3				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).



ICD-10 C74: Malignant neoplasm of adrenal gland

Figure 6. Age distribution (males: mean=48.8 yrs, median=56.8 yrs; females: mean=53.1 yrs, median=58.6 yrs) and age-specific incidence.






Figure 6a. Age-specific incidence in MCR registry areas compared to Germany (FRG, RKI estimates) and SEER (Surveillance, Epidemiology, and End Results, USA).



Reference:

Estimated age-specific patient population of Germany, latest update: 16 March 2021. German Centre for Cancer Registry Data, Robert Koch Institute (RKI), based on data of the population based cancer registries. http://www.krebsdaten.de. Last access: 08/17/2021 Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 21 Regs Research Data, released April 2021, based on the November 2020 submission. http://www.seer.cancer.gov.

Table 7a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998-2020 MALES

	Observed Ex	pected		CI	CI		DCO
Diagnosis	/ n /	n	SIR	95%	95%	EAR	00
C18 Colon	/ 1 /	0.4	2.6	0.1	14.6	13.0	
C33-C34 Lung	/ 1 /	0.5	2.1	0.1	11.9	11.2	
C43 Malign. melanoma	2	0.2	11.2	1.4	40.4	# 38.3	
C46,C49 Soft tissue	2	0.0	79.3	9.6	286.5	# 41.5	
C61 Prostate	3	1.0	2.9	0.6	8.4	41.0	
C64 Kidney	1	0.1	7.1	0.2	39.4	18.1	
C73 Thyroid	2	0.0	66.1	8.0	238.9	# 41.4	
C74-C80 Cancer others	2	0.0	208.5	25.3	753.3	# 41.9	
C82-C85 NHL	1	0.2	5.8	0.1	32.5	17.4	
C91-C96 Leukaemia	1	0.1	14.6	0.4	81.5	19.6	
Not observed	0	1.5	0.0	0.0	2.5	-30.5	
All further malignancies	16	4.0	4.0	2.3	6.5	# 252.9	
Patients		128	3				
Median age at next malignar	ncy (years)	66.8	3				
Person-years		476	5				
Mean observation time (year	cs)	3.7	7				
Median observation time (ye		1.6					
	· ·						

The occurrence of further specified malignancy is statistically significant.




Table 7b

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998-2020 FEMALES

	Observed 2	Expected		CI	CI		DCO
Diagnosis	n	n	SIR	95%	95%	EAR	90
C16 Stomach	/ 1 /	0.1	9.1	0.2	50.7	16.2	
C17 Small intestine	/ 1/	0.0	52.6	1.3	293.3 #	17.9	
C22 Liver	/ 1/	0.0	25.0	0.6	139.3	17.5	100.0
C33-C34 Lung	2	0.3	7.7	0.9	28.0	31.8	
C43 Malign. melanoma	1	0.1	6.8	0.2	37.9	15.6	
C46,C49 Soft tissue	2	0.0	88.6	10.7	320.2 #	36.1	
C50 Breast	1	1.1	0.9	0.0	5.0	-2.1	
C73 Thyroid	1	0.1	13.1	0.3	72.9	16.8	
Not observed	0	1.8	0.0	0.0	2.1	-32.0	
All further malignancies	10	3.5	2.8	1.4	5.2 #	117.9	10.0
Patients		147					
Median age at next maligna	ncy (years) 65.4					
Person-years		548					
Mean observation time (yea	rs)	3.7					
Median observation time (y	ears)	2.5					

The occurrence of further specified malignancy is statistically significant.





Average incidence (Germany 1987 standard population) 2007 - 2020: Males

verage incidence (Germany 1987 standard population) 2007 - 2020: Females





Figure 8a. Map of cancer incidence (german standard population, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual incidence rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.3/100,000 WS N=94, females 0.3/100,000 WS N=107).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,727 female residents (averaged) in the period from 2007 to 2020 a total of 3 women were identified with newly diagnosed adrenal cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.3/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.1/100,000.



Standardized incidence ratio (SIR) 2007 - 2020: Males

Standardized incidence ratio (SIR) 2007 - 2020: Females




Figure 8b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual SIR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=94, females N=107).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2020 a total of 3 women were identified with newly diagnosed adrenal cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.02. Though, the value of this parameter may vary with an underlying probability of 99% between 0.12 and 3.74, and is therefore not statistically striking.

MORTALITY

Table 9a

Annual cohorts: Incident cancers, follow-up status, proportion of DCO, deaths among the annual cohorts and proportion of available death certificates (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

						Prop.
		Prop.				deaths
	Incident	actively	Prop.		Prop.	with death
Year of	cases	followed	DCO	Deaths	deaths	certific.
diagnosis	n	90	00	n	90	90
1998	8	100.0		3	37.5	100.0
1999	7	100.0	14.3	6	85.7	100.0
2000	9	100.0	11.1	7	77.8	85.7
2001	9 7	88.9	11.1	5	55.6	80.0
2002	7	100.0		6	85.7	100.0
2003	11	100.0	9.1	8	72.7	100.0
2004	16	100.0	6.3	9	56.3	100.0
2005	12	83.3	16.7	6	50.0	83.3
2006	13	100.0		10	76.9	100.0
2007	12	100.0		7	58.3	100.0
2008	10	100.0		7	70.0	100.0
2009	15	100.0	6.7	7	46.7	100.0
2010	16	93.8		12	75.0	83.3
2011	17	100.0		9	52.9	77.8
2012	18	88.9	16.7	11	61.1	100.0
2013	22	100.0	9.1	9	40.9	88.9
2014	20	95.0	10.0	13	65.0	100.0
2015	14	100.0		10	71.4	80.0
2016	16	100.0	12.5	9	56.3	88.9
2017	15	100.0	13.3	7	46.7	71.4
2018	12	100.0		6	50.0	33.3
2019	8	100.0		4	50.0	100.0
2020	7	100.0		1	14.3	100.0
1998-2020	294	97.6	6.5	172	58.5	90.1



Table 9b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased within the same year of being diagnosed with cancer (incl. DCO)

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

			Prop.		
			deaths		Prop.
Year of	Incident		with death	Deaths in	deaths in
diagnosis/	cases	Deaths	certific.	same year	same year
death	n	n	90	n	00
1998	8	4	100.0		
1999	7	4	100.0	1	14.3
2000	9	3	66.7		
2001	9	6	100.0	2	22.2
2002	7	8	100.0	2	28.6
2003	11	7	100.0	3	27.3
2004	16	7	85.7	2	12.5
2005	12	7	100.0	3	25.0
2006	13	5	100.0		
2007	12	6	100.0		
2008	10	11	100.0	3	30.0
2009	15	8	100.0	1	6.7
2010	16	7	100.0	2	12.5
2011	17	10	90.0	2	11.8
2012	18	14	100.0	5	27.8
2013	22	15	100.0	5 3 6	13.6
2014	20	13	100.0		30.0
2015	14	13	100.0	2	14.3
2016	16	14	100.0	6	37.5
2017	15	4	100.0	2	13.3
2018	12	9	44.4	2	16.7
2019	8	9	11.1	1	12.5
2020	7	8	87.5		
1998-2020	294	192	91.1	48	16.3



Table 9c

Annual cohorts of deaths, proportion of cancer-related and non-cancerrelated deaths, and cancer recorded on death certificates (incl. DCO) (with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.94 m as of 2007, respectively)

				Prop.	
				cancer	
		Prop.	Prop.	recorded	
		cancer-	non-cancer-	on death	
Year of	Deaths	related	related	certificate	
death	n	00	90	8	
1998	4	100.0		100.0	
1999	4	100.0		100.0	
2000	3	100.0		100.0	
2001	6	100.0		100.0	
2002	8	100.0		87.5	
2003	7	100.0		100.0	
2004	7	85.7	14.3	83.3	
2005	7	100.0		100.0	
2006	5	80.0	20.0	80.0	
2007	6	100.0		100.0	
2008	11	90.9	9.1	90.9	
2009	8	87.5	12.5	87.5	
2010	7	85.7	14.3	100.0	
2011	10	70.0	30.0	100.0	
2012	14	92.9	7.1	100.0	
2013	15	93.3	6.7	100.0	
2014	13	84.6	15.4	92.3	
2015	13	100.0		92.3	
2016	14	78.6	21.4	78.6	
2017	4	100.0		100.0	
2018	9	44.4	55.6	75.0	
2019	9	55.6	44.4	100.0	
2020	8	87.5	12.5	85.7	
1998-2020	192	87.0	13.0	93.1	



Table 10a

Medians of age at death according to the grouping in Table 9 $$\rm MALES$$

					Age at
		Age at	Age at	Age at	death
		death	death	death	(according
		(all	(cancer-	(non-cancer-	to death
Year of	Deaths	causes)	related)	related)	certificate)
death	n	Years	Years	Years	Years
1998					
1999	1	48.2	48.2		48.2
2000	1	4.2	4.2		
2001	4	64.2	64.2		64.2
2002	2	27.6	27.6		27.6
2003					
2004	3	70.9	70.9		70.9
2005	3	78.7	78.7		78.7
2006	3	65.8	67.3	51.8	67.3
2007	2	58.8	58.8		58.8
2008	5	56.4	56.4		56.4
2009	3	66.8	60.4	80.5	60.4
2010	5 3 5 4	39.1	21.6	82.1	39.1
2011		70.1	60.6	79.6	70.1
2012	6	58.8	50.9	75.1	58.8
2013	7	62.2	62.2		62.2
2014	4	72.5	72.5		72.5
2015	6	75.8	75.8		75.8
2016	5	49.0	49.0		49.0
2017	1	75.8	75.8		75.8
2018	4	67.2	68.5	67.2	80.0
2019	4	81.4	85.6	81.4	
2020	5	61.4	52.7	78.6	44.1
1998-2020	78	65.2	63.8	78.7	64.1

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 10b

Medians of age at death according to the grouping in Table 9 $$\operatorname{FEMALES}$

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer- related) Years	Age at death (non-cancer- related) Years	Age at death (according to death certificate) Years
1998	4	69.2	69.2		69.2
1999	3	72.0	72.0		72.0
2000	2	66.7	66.7		66.7
2001	2	66.8	66.8		66.8
2002	6	70.8	70.8		73.1
2003	7	68.1	68.1		68.1
2004	4	54.1	35.5	82.3	52.5
2005	4	70.6	70.6		70.6
2006	2	62.2	62.2		62.2
2007	4	47.6	47.6		47.6
2008	6	64.4	58.1	83.6	58.1
2009	5	57.5	57.5		57.5
2010	2	64.6	64.6		64.6
2011	6	46.2	51.7	31.2	62.4
2012	8	54.9	54.9		54.9
2013	8	74.6	69.7	93.9	74.6
2014	9	76.1	76.1	85.1	80.3
2015	7	82.4	82.4		72.0
2016	9	83.2	65.0	88.9	65.0
2017	3	75.5	75.5		75.5
2018	5	57.1	57.9	57.1	57.9
2019	5	76.7	58.7	81.9	58.7
2020	3	46.7	46.7		46.7
1998-2020	114	67.8	66.1	83.6	66.8

By 2018, Bavarians' life expectancy at birth is estimated at 79.3 years for boys and 83.8 years for girls.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11a

Mortality measures (cancer-related death) and mortality-incidence-index by year of death MALES

Year of	Deaths	Mort.	MI-Index	Mort	MT-Index	Mort.	MT-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
		-		/	-			-	-
1998									
1999	1	0.1	0.50	0.1	0.33	0.1	0.45	0.1	0.60
2000	1	0.1	0.17	0.2	0.44	0.1	0.27	0.1	0.15
2001	4	0.3	1.33	0.2	0.48	0.3	0.82	0.3	1.22
2002	2	0.1	0.67	0.2	0.56	0.1	0.64	0.1	0.65
2003									
2004	3	0.2	0.43	0.1	0.45	0.1	0.41	0.2	0.36
2005	3	0.2	0.38	0.1	0.12	0.1	0.26	0.2	0.45
2006	2	0.1	0.33	0.1	0.26	0.1	0.26	0.1	0.25
2007	2	0.1	0.33	0.1	0.15	0.1	0.21	0.1	0.27
2008	5	0.2	1.67	0.2	2.16	0.2	1.70	0.2	1.84
2009	2	0.1	0.33	0.1	0.20	0.1	0.27	0.1	0.31
2010	4	0.2	0.57	0.3	0.51	0.2	0.53	0.2	0.49
2011	3	0.1	0.33	0.2	0.31	0.1	0.30	0.1	0.36
2012	5	0.2	0.45	0.1	0.29	0.2	0.37	0.2	0.40
2013	7	0.3	0.64	0.3	0.49	0.3	0.57	0.3	0.64
2014	4	0.2	0.40	0.1	0.55	0.2	0.46	0.2	0.42
2015	6	0.3	1.20	0.1	0.51	0.2	0.78	0.2	1.22
2016	5	0.2	0.56	0.2	0.71	0.2	0.65	0.2	0.57
2017	1	0.0	0.17	0.0	0.06	0.0	0.09	0.0	0.14
2018	2	0.1	0.40	0.0	0.51	0.0	0.45	0.1	0.38
2019	2	0.1	0.67	0.0	0.25	0.0	0.39	0.1	0.60
2020	4	0.2	1.33	0.1	1.85	0.1	1.52	0.2	1.40
1998-2020	68	0.1	0.51	0.1	0.40	0.1	0.46	0.1	0.51

Table 11b

Mortality measures (cancer-related death) and mortality-incidence-index by year of death FEMALES

Year of	Deaths	Mort	MT-Index	Mort	MI-Index	Mort	MI-Index	Mort	MI-Index
death	n	raw	raw	WS	WS	ES ES	ES	BRD-S	BRD-S
ucacii	11	Law	Law	115	WB		ШS	DIG 5	DILD 5
1998	4	0.3	0.57	0.2	0.26	0.3	0.41	0.3	0.55
1999	3	0.3	0.60	0.1	0.49	0.2	0.56	0.2	0.59
2000	2	0.2	0.67	0.1	0.34	0.1	0.47	0.1	0.50
2001	2	0.2	0.33	0.1	0.14	0.1	0.24	0.2	0.31
2002	6	0.3	1.50	0.3	1.19	0.3	1.27	0.3	1.42
2003	7	0.4	0.88	0.2	0.45	0.2	0.62	0.3	0.82
2004	3	0.2	0.33	0.1	0.14	0.1	0.23	0.1	0.31
2005	4	0.2	1.00	0.1	0.46	0.1	0.72	0.2	0.87
2006	2	0.1	0.29	0.1	0.30	0.1	0.32	0.1	0.31
2007	4	0.2	0.67	0.2	0.50	0.2	0.61	0.2	0.65
2008	5	0.2	0.71	0.1	0.54	0.2	0.77	0.2	0.68
2009	5	0.2	0.56	0.2	0.71	0.2	0.62	0.2	0.52
2010	2	0.1	0.22	0.1	0.16	0.1	0.20	0.1	0.20
2011	4	0.2	0.50	0.1	0.30	0.1	0.34	0.2	0.50
2012	8	0.3	1.14	0.2	1.00	0.3	1.24	0.3	1.49
2013	7	0.3	0.70	0.1	0.50	0.2	0.61	0.2	0.70
2014	7	0.3	0.70	0.1	0.39	0.1	0.50	0.2	0.56
2015	7	0.3	0.78	0.1	0.31	0.2	0.46	0.2	0.58
2016	6	0.2	0.86	0.2	0.77	0.2	0.74	0.2	0.79
2017	3	0.1	0.33	0.0	0.14	0.1	0.20	0.1	0.30
2018	2	0.1	0.29	0.1	0.20	0.1	0.25	0.1	0.23
2019	3	0.1	0.60	0.1	0.49	0.1	0.50	0.1	0.47
2020	3	0.1	0.75	0.1	1.06	0.1	0.92	0.1	0.86
1998-2020	99	0.2	0.62	0.1	0.41	0.2	0.51	0.2	0.57

12/21/2021

Age distribution of age at death (cancer-related) for period 2007-2020 (incl. multiple malignancies)

Age at									
death	Cases			Males			Females		
Years	n	00	Cum.%	n	olo	Cum.%	n	olo	Cum.%
0-4	6	5.1	5.1	4	7.7	7.7	2	3.0	3.0
5-9	1	0.8	5.9	1	1.9	9.6			3.0
10-14	2	1.7	7.6	1	1.9	11.5	1	1.5	4.5
15-19	1	0.8	8.5	1	1.9	13.5			4.5
20-24	1	0.8	9.3	1	1.9	15.4			4.5
25-29	5	4.2	13.6	1	1.9	17.3	4	6.1	10.6
30-34	0	0.0	13.6			17.3			10.6
35-39	3	2.5	16.1	1	1.9	19.2	2	3.0	13.6
40-44	5	4.2	20.3	2	3.8	23.1	3	4.5	18.2
45-49	9	7.6	28.0	5	9.6	32.7	4	6.1	24.2
50-54	6	5.1	33.1	2	3.8	36.5	4	6.1	30.3
55-59	9	7.6	40.7	3	5.8	42.3	6	9.1	39.4
60-64	15	12.7	53.4	7	13.5	55.8	8	12.1	51.5
65-69	12	10.2	63.6	5	9.6	65.4	7	10.6	62.1
70-74	10	8.5	72.0	6	11.5	76.9	4	6.1	68.2
75-79	11	9.3	81.4	5	9.6	86.5	6	9.1	77.3
80-84	11	9.3	90.7	4	7.7	94.2	7	10.6	87.9
85+	11	9.3	100.0	3	5.8	100.0	8	12.1	100.0
All ages	118	100.0		52	100.0		66	100.0	

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2020 (incl. multiple malignancies)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females			spec.		cancers	cancers
Years	n	n	/ = /	MI-index	-	MI-index		90
] -			
0- 4	4	2	0.2	0.24	0.1	0.20	21.1	12.5
5-9	1	/	0.1	1.00		0.120	3.6	12.0
10-14	1	1	0.1	1.00	0.1	1.00	3.6	4.3
15-19	1	- [0.1		0.1	1.00	2.1	1.0
20-24	1		0.0	0.33			1.4	
25-29	1	4	0.0		0.2	0.40	1.1	4.0
30-34	1	L.	0.0	0.50	0.2	0.40	- • -	4.0
35-39	1	2	0.0	0.33	0.1	0.40	0.4	0.5
40-44	2	3	0.0		0.1		0.3	0.4
45-49	5	4	0.1	0.30	0.1	0.43	0.3	0.4
4J-49 50-54	2	4	0.2		0.2		0.4	0.2
	2							
55-59		6	0.1	0.25	0.3		0.1	0.2
60-64	7	8	0.4	0.58	0.4		0.1	0.2
65-69	5	7	0.3	1.00	0.4		0.1	0.1
70-74	6	4	0.4		0.2		0.1	0.0
75-79	5	6	0.4		0.4		0.0	0.1
80-84	4	7	0.6		0.7		0.0	0.1
85+	3	8	0.6	3.00	0.8	0.89	0.0	0.1
All ages	52	66					0.1	0.1
-								
Mortality								
Raw			0.2	0.55	0.2	0.62		
WS			0.1		0.1	0.45		
ES			0.1	0.50	0.1			
BRD-S			0.2	0.55	0.2			
PYLL-70								
per 100,000			3.0		2.9			
ES			3.5		3.0			
AYLL-70			25.6		20.1			

Table 14a

Further malignancies in deaths in period 1998-2020 $${\rm MALES}$$

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n	%↓	n	~%	n	00	n	6→
C16 Stomach C33-C34 Lung	1	4.2	1	100.0			1	100.0
C43 Malign. melanoma	3	12.5	2	66.7			1	33.3
C44 Skin others	7	29.2	_				7	100.0
C46,C49 Soft tissue	2	8.3			1	50.0	1	50.0
C61 Prostate	3	12.5	2	66.7			1	33.3
C62 Testis	1	4.2	1	100.0				
C64 Kidney	2	8.3	1	50.0			1	50.0
C67 Bladder	1	4.2	1	100.0				
C73 Thyroid	1	4.2					1	100.0
C76-C79 CUP	1	4.2	1	100.0				
C91-C96 Leukaemia	1	4.2					1	100.0
All further malignancies	24	100.0	9	37.5	1	4.2	14	58.3

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 14b

Further malignancies in deaths in period 1998-2020 FEMALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n	%↓	n	⇔%	n	⇔%	n	~%
C16 Stomach	1	4.5					1	100.0
C17 Small intestine	1	4.5					1	100.0
C22 Liver	1	4.5					1	100.0
C33-C34 Lung	3	13.6			2	66.7	1	33.3
C43 Malign. melanoma	1	4.5					1	100.0
C44 Skin others	1	4.5	1	100.0				
C46,C49 Soft tissue	2	9.1			1	50.0	1	50.0
C50 Breast	4	18.2	4	100.0				
C54 Corpus uteri	4	18.2	4	100.0				
C64 Kidney	1	4.5			1	100.0		
C67 Bladder	2	9.1			1	50.0	1	50.0
C73 Thyroid	1	4.5			1	100.0		
All further malignancies	22	100.0	9	40.9	6	27.3	7	31.8

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2020 (First primaries only *)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal. 1	MI-index	00	00
0- 4	4	2	0.2	0.24	0.1	0.20	21.1	13.3
5- 9	1		0.1	1.00			3.7	
10-14	1	1 /	0.1	1.00	0.1	1.00	3.6	5.3
15-19	1		0.1	1.00			2.2	
20-24	1		0.0	0.33			1.5	
25-29	1	4	0.0	1.00	0.2	0.44	1.2	4.4
30-34								
35-39	1	2	0.0	0.33	0.1	0.40	0.4	0.5
40 - 44	2	3	0.1	0.50	0.1	0.50	0.4	0.4
45-49	4	4	0.1	1.33	0.2	0.67	0.3	0.3
50-54	2	4	0.1	0.40	0.2	1.33	0.1	0.2
55-59	3	6	0.1	0.30	0.3	0.60	0.1	0.2
60-64	5	7	0.3	0.71	0.4	0.88	0.1	0.2
65-69	5	6	0.3	1.25	0.3	1.00	0.1	0.1
70-74	5	4	0.3	0.71	0.2	0.80	0.1	0.1
75-79	3	6	0.2	0.60	0.4	1.50	0.0	0.1
80-84	2	6	0.3	1.00	0.6	0.86	0.0	0.1
85+	3	5	0.6	3.00	0.5	0.71	0.0	0.1
All ages	44	60					0.1	0.1
5								
Mortality								
Raw _			0.1	0.60	0.2	0.66		
WS			0.1	0.48	0.1	0.48		
ES			0.1	0.54	0.1	0.56		
BRD-S			0.1	0.60	0.2	0.62		
PYLL-70								
per 100,000			2.9		2.9			
ES			3.4		3.0			
AYLL-70			26.9		20.8			

* See corresponding tables with multiple malignancies.

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2020 (Single primaries only *)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	00	00
0- 4	4	1	0.2	0.24	0.1	0.11	21.1	6.7
5- 9	1		0.1	1.00			3.7	
10-14	1	1 /	0.1	1.00	0.1	1.00	3.6	5.3
15-19	1		0.1	1.00			2.2	
20-24	1		0.0	0.33			1.5	
25-29	1	4	0.0	1.00	0.2	0.44	1.2	4.5
30-34								
35-39	1	2	0.0	0.33	0.1	0.40	0.4	0.5
40-44	2	3	0.1	0.50	0.1	0.50	0.4	0.4
45-49	4	4	0.1	1.33	0.2	0.67	0.3	0.3
50-54	1	4	0.0	0.20	0.2	2.00	0.0	0.2
55-59	3	6	0.1	0.30	0.3	0.60	0.1	0.2
60-64	5	6	0.3	0.71	0.3	0.75	0.1	0.2
65-69	4	6	0.2	1.00	0.3	1.50	0.1	0.1
70-74	4	3	0.3	0.57	0.2	0.60	0.0	0.0
75-79	3	6	0.2	0.60	0.4	1.50	0.0	0.1
80-84	2	6	0.3	1.00	0.6	0.86	0.0	0.1
85+	1	5	0.2		0.5	0.83	0.0	0.1
All ages	39	57					0.1	0.1
2								
Mortality								
Raw			0.1	0.53	0.2	0.66		
WS			0.1		0.1	0.46		
ES			0.1	0.49	0.1	0.55		
BRD-S			0.1	0.54	0.1	0.61		
PYLL-70								
per 100,00	0		2.8		2.6			
ES	-		3.4		2.6			
AYLL-70			28.0		19.9			

* See corresponding tables with multiple malignancies.





Figure 17. Distribution of age at death (bars; males: mean=53.0 yrs, median=60.2 yrs; females: mean=58.6 yrs, median=61.1 yrs) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at adrenal cancer-related death (see Table 10) should be considered.





verage mortality (Germany 1987 standard population) 2007 - 2020: Males

Average mortality (Germany 1987 standard population) 2007 - 2020: Females





Figure 18a. Map of cancer mortality (german standard population) by county averaged for period 2007 to 2020. According to their individual mortality rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.2/100,000 WS N=52, females 0.2/100,000 WS N=66).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,727 female residents (averaged) in the period from 2007 to 2020 a total of 2 women died from adrenal cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.2/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 0.9/100,000.



Standardized mortality ratio (SMR) 2007 - 2020: Males

Standardized mortality ratio (SMR) 2007 - 2020: Females



Figure 18b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2020. According to their individual SMR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=52, females N=66).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2020 a total of 2 women died from adrenal cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 1.11. Though, the value of this parameter may vary with an underlying probability of 99% between 0.06 and 5.14, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases, where applicable. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head&neck and lung).

The ratio of mortality and incidence (mortality-to-incidence ratio, **MIR**, **MI-Index**) is a statistical index that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MIR. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

MCR	Munich Cancer Registry (Tumorregister München)
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
SEER	Surveillance, Epidemiology, and End Results (USA)
DCO	Death certificate only
BRD-S	German (FRG) standard population
ES WS	European standard population (old) World standard population
VV0	Wond standard population
SIR	Standardized incidence ratio
CI EAR	Confidence interval Excess absolute risk
	= excess cancer cases (O - E) per 10,000 person-years
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
SMR	Standardized mortality ratio
MI-index	Ratio of mortality to incidence, MIR
FRG	Enderel Benublic of Cormony
FRG	Federal Republic of Germany

Recommended Citation

Munich Cancer Registry. ICD-10 C74: Adrenal cancer - Incidence and Mortality [Internet]. 2021 [updated 2021 Dec 21; cited 2022 Feb 1]. Available from: https://www.tumorregistermuenchen.de/en/facts/base/bC74_E-ICD-10-C74-Adrenal-cancer-incidence-and-mortality.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.